Oncolytics Biotech
American biotechnology company
Toronto Stock Exchange · home listing
ONCY Nasdaq
SEC CIK 1129928
Follow Oncolytics Biotech
Weekly email: filings, results
Net income
−$9.7M
+1.8% vs same quarter last year
EPS, diluted
−$0.08
+20% vs same quarter last year
Operating cash flow
−$6.9M
−42.8% vs same quarter last year
Operating income
−$9.7M
−1.9% vs same quarter last year
Source: SEC XBRL filings · latest filing